These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38784143)

  • 1. High-risk Individuals and Naloxone Use: Implications for THN Programs in Rural Appalachian Communities.
    Garcia V; McCann L; Lauber E; Vaccaro C; Swauger M; Heckert AD
    J Appalach Health; 2023; 5(3):9-21. PubMed ID: 38784143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioid Overdoses and Take-Home Naloxone Interventions: Ethnographic Evidence for Individual-Level Barriers to Treatment of Opioid Use Disorders in Rural Appalachia.
    Garcia V; McCann L; Lauber E; Vaccaro C; Swauger M; Heckert DA
    Subst Use Misuse; 2024; 59(9):1313-1322. PubMed ID: 38635977
    [No Abstract]   [Full Text] [Related]  

  • 3. A study protocol for a European, mixed methods, prospective, cohort study of the effectiveness of naloxone administration by community members, in reversing opioid overdose: NalPORS.
    Metrebian N; Carter B; Eide D; McDonald R; Neale J; Parkin S; Dascal T; Mackie C; Day E; Guterstam J; Horsburgh K; Kåberg M; Kelleher M; Smith J; Thiesen H; Strang J
    BMC Public Health; 2023 Aug; 23(1):1608. PubMed ID: 37612698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review of the distribution of take-home naloxone in low- and middle-income countries and barriers to the implementation of take-home naloxone programs.
    Sajwani HS; Williams AV
    Harm Reduct J; 2022 Oct; 19(1):117. PubMed ID: 36266701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designing, implementing and evaluating the overdose response with take-home naloxone model of care: An evaluation of client outcomes and perspectives.
    Lintzeris N; Monds LA; Bravo M; Read P; Harrod ME; Gilliver R; Wood W; Nielsen S; Dietze PM; Lenton S; Shanahan M; Jauncey M; Jefferies M; Hazelwood S; Dunlop AJ; Greenaway M; Haber P; Ezard N; Malcom A
    Drug Alcohol Rev; 2020 Jan; 39(1):55-65. PubMed ID: 31774221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twenty years of take-home naloxone for the prevention of overdose deaths from heroin and other opioids-Conception and maturation.
    McDonald R; Campbell ND; Strang J
    Drug Alcohol Depend; 2017 Sep; 178():176-187. PubMed ID: 28654870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overdose and take-home naloxone in emergency settings: A pilot study examining feasibility of delivering brief interventions addressing overdose prevention with 'take-home naloxone' in emergency departments.
    Black E; Monds LA; Chan B; Brett J; Hutton JE; Acheson L; Penm J; Harding S; Strumpman D; Demirkol A; Lintzeris N
    Emerg Med Australas; 2022 Aug; 34(4):509-518. PubMed ID: 35021268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of take-home naloxone in the epidemic of opioid overdose involving illicitly manufactured fentanyl and its analogs.
    Kim HK; Connors NJ; Mazer-Amirshahi ME
    Expert Opin Drug Saf; 2019 Jun; 18(6):465-475. PubMed ID: 31033357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Narcan encounters:" overdose and naloxone rescue experiences among people who use opioids.
    Kahn LS; Wozniak M; Vest BM; Moore C
    Subst Abus; 2022; 43(1):113-126. PubMed ID: 32243234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Take-Home Naloxone and risk management from the perspective of people who survived an opioid overdose in Stockholm - An analysis informed by drug, set and setting.
    Holmén E; Hammarberg A; Kåberg M; Storbjörk J
    Int J Drug Policy; 2023 May; 115():104021. PubMed ID: 37011507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design details for overdose education and take-home naloxone kits: Codesign with family medicine, emergency department, addictions medicine and community.
    Sellen K; Goso N; Halleran L; Mulvale-Fletcher A; Sarmiento F; Ligabue F; Handford C; Klaiman M; Milos G; Wright A; Charles M; Sniderman R; Hunt R; Parsons JA; Leece P; Hopkins S; Shahin R; Jüni P; Morrison L; Campbell DM; Strike C; Orkin A;
    Health Expect; 2022 Oct; 25(5):2440-2452. PubMed ID: 35909312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protocol for Take-home naloxone In Multicentre Emergency (TIME) settings: feasibility study.
    Jones M; Bell F; Benger J; Black S; Buykx P; Dixon S; Driscoll T; Evans B; Edwards A; Fuller G; Goodacre S; Hoskins R; Hughes J; John A; Jones J; Moore C; Sampson F; Watkins A; Snooks H
    Pilot Feasibility Stud; 2020; 6():96. PubMed ID: 32670598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Take-home naloxone programs for suspected opioid overdose in community settings: a scoping umbrella review.
    Moustaqim-Barrette A; Dhillon D; Ng J; Sundvick K; Ali F; Elton-Marshall T; Leece P; Rittenbach K; Ferguson M; Buxton JA
    BMC Public Health; 2021 Mar; 21(1):597. PubMed ID: 33771150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Awareness, Possession, and Use of Take-Home Naloxone Among Illicit Drug Users, Vancouver, British Columbia, 2014-2015.
    Nolan S; Buxton J; Dobrer S; Dong H; Hayashi K; Milloy MJ; Kerr T; Montaner J; Wood E
    Public Health Rep; 2017; 132(5):563-569. PubMed ID: 28750193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient characteristics associated with being offered take home naloxone in a busy, urban emergency department: a retrospective chart review.
    O'Brien DC; Dabbs D; Dong K; Veugelers PJ; Hyshka E
    BMC Health Serv Res; 2019 Sep; 19(1):632. PubMed ID: 31488142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polysubstance use in rural West Virginia: Associations between latent classes of drug use, overdose, and take-home naloxone.
    Schneider KE; O'Rourke A; White RH; Park JN; Musci RJ; Kilkenny ME; Sherman SG; Allen ST
    Int J Drug Policy; 2020 Feb; 76():102642. PubMed ID: 31918401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A qualitative study of repeat naloxone administrations during opioid overdose intervention by people who use opioids in New York City.
    Parkin S; Neale J; Brown C; Jones JD; Brandt L; Castillo F; Campbell ANC; Strang J; Comer SD
    Int J Drug Policy; 2021 Jan; 87():102968. PubMed ID: 33096365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does naloxone provision lead to increased substance use? A systematic review to assess if there is evidence of a 'moral hazard' associated with naloxone supply.
    Tse WC; Djordjevic F; Borja V; Picco L; Lam T; Olsen A; Larney S; Dietze P; Nielsen S
    Int J Drug Policy; 2022 Feb; 100():103513. PubMed ID: 34798434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knowledge of Opioid Overdose and Attitudes to Supply of Take-Home Naloxone Among People with Chronic Noncancer Pain Prescribed Opioids.
    Nielsen S; Peacock A; Lintzeris N; Bruno R; Larance B; Degenhardt L
    Pain Med; 2018 Mar; 19(3):533-540. PubMed ID: 28340185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naloxone and the Inner City Youth Experience (NICYE): a community-based participatory research study examining young people's perceptions of the BC take home naloxone program.
    Mitchell K; Durante SE; Pellatt K; Richardson CG; Mathias S; Buxton JA
    Harm Reduct J; 2017 Jun; 14(1):34. PubMed ID: 28592287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.